((6-cyclohexyl-4-methylpyridin-1(2H)-yl)oxy)methyl dihydrogen phosphate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机磷酸及其衍生物
• 英文名称: ((6-cyclohexyl-4-methylpyridin-1(2H)-yl)oxy)methyl dihydrogen phosphate
• 英文别名: (6-cyclohexyl-4-methyl-2H-pyridin-1-yl)oxymethyl dihydrogen phosphate
• 化学式: C₁₃H₂₂NO₅P
• 分子量: 303.295
• InChiKey: BOHAJGAEHIRNCQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  20
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.69
• 拓扑面积：
  79.2
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  ((6-cyclohexyl-4-methylpyridin-1(2H)-yl)oxy)methyl dihydrogen phosphate 在 sodium 作用下， 生成 ((6-cyclohexyl-4-methylpyridin-1(2H)-yl)oxy)methyl phosphate disodium salt
  参考文献：
  名称：

  [EN] METHODS OF BLADDER CANCER TREATMENT WITH CICLOPIROX, CICLOPIROX OLAMINE, OR A CICLOPIROX PRODRUG
  [FR] PROCÉDÉS DE TRAITEMENT DU CANCER DE LA VESSIE AVEC LE CICLOPIROX, LE CICLOPIROX OLAMINE OU UN PROMÉDICAMENT À BASE DE CICLOPIROX

  摘要：

  提供了一种治疗膀胱癌的方法。治疗膀胱癌的方法可以包括：提供含有环丙沙星或环丙沙星醇胺或具有本文提供的任一式的结构或其衍生物或立体异构体或其药用可接受盐的环丙沙星-POM前药的药物组合物；并将该药物组合物给予患有膀胱癌的受试者。环丙沙星或环丙沙星醇胺或环丙沙星-POM前药可以以治疗有效量进行给予。

  公开号：

  WO2016077346A1
• 作为产物：
  描述：

  环吡司胺 在 盐酸 、 palladium on activated charcoal 、 氢气 、 sodium hydride 作用下， 以 四氢呋喃 、 水 、 乙酸乙酯 、 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 反应 4.5h， 生成 ((6-cyclohexyl-4-methylpyridin-1(2H)-yl)oxy)methyl dihydrogen phosphate 、 ((6-cyclohexyl-4-methylpyridin-1(2H)-yl)oxy)methyl phosphate disodium salt
  参考文献：
  名称：

  [EN] METHODS OF BLADDER CANCER TREATMENT WITH CICLOPIROX, CICLOPIROX OLAMINE, OR A CICLOPIROX PRODRUG
  [FR] PROCÉDÉS DE TRAITEMENT DU CANCER DE LA VESSIE AVEC LE CICLOPIROX, LE CICLOPIROX OLAMINE OU UN PROMÉDICAMENT À BASE DE CICLOPIROX

  摘要：

  提供了一种治疗膀胱癌的方法。治疗膀胱癌的方法可以包括：提供含有环丙沙星或环丙沙星醇胺或具有本文提供的任一式的结构或其衍生物或立体异构体或其药用可接受盐的环丙沙星-POM前药的药物组合物；并将该药物组合物给予患有膀胱癌的受试者。环丙沙星或环丙沙星醇胺或环丙沙星-POM前药可以以治疗有效量进行给予。

  公开号：

  WO2016077346A1

文献信息

• METHOD OF TREATMENT WITH PRODRUGS OF 6-CYCLOHEXYL-1-HYDROXY-4-METHYLPYRIDIN IN-2-1H-ONE AND DERIVATIVES THEREOF
  申请人：Tanol Mehmet

  公开号：US20150111858A1

  公开（公告）日：2015-04-23

  A prodrug can have a structure of Formula 10 or derivative thereof or stereoisomer thereof or pharmaceutically acceptable salt thereof. The prodrug can be included in a pharmaceutical composition for use in treatment of fungus, cancer, dermatitis, superficial mycoses; inflammation, tinea pedis, tinea cruris, and tinea corporis, Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyton floccosum , and Microsporum canis , candidiasis (moniliasis), Candida albicans , tinea ( pityriasis ) vesicolor, Malassezia furfur , acute myeloid leukemia, acute lymphoid leukemia, chronic myelogenous leukemia, lymphoma or multiple myeloma.

  前药可以具有公式10的结构或其衍生物或立体异构体或药物可接受的盐。该前药可包含在用于治疗真菌、癌症、皮炎、浅部真菌病；炎症、足癣、股癣、体癣、红色毛癣菌、须毛癣菌、絮状表皮癣菌和犬小孢子菌、念珠菌病（ moniliasis）、白念珠菌、癣（白斑）变色、糠秕马拉色菌、急性髓系白血病、急性淋巴细胞白血病、慢性粒细胞白血病、淋巴瘤或多发性骨髓瘤的药物组合物中。
• PRODRUGS OF 6-CYCLOHEXYL-1-HYDROXY-4- METHYLPYRIDIN-2(1H)-ONE AND DERIVATIVES THEREOF
  申请人：THE UNIVERSITY OF KANSAS

  公开号：EP2646035B1

  公开（公告）日：2016-03-09
• CICLOPIROX, CICLOPIROX OLAMINE, OR A CICLOPIROX PRODRUG FOR USE IN THE TREATMENT OF BLADDER CANCER
  申请人：The University of Kansas

  公开号：EP3217980B1

  公开（公告）日：2020-10-14
• PRODRUGS OF 6-CYCLOHEXYL-1-HYDROXY-4-METHYLPYRIDIN-2-(1H)- ONE AND DERIVATIVES THEREOF
  申请人：Tanol Mehmet

  公开号：US20120142637A1

  公开（公告）日：2012-06-07

  A prodrug can have a structure of Formula 10 or derivative thereof or stereoisomer thereof or pharmaceutically acceptable salt thereof. The prodrug can be included in a pharmaceutical composition for use in treatment of fungus, cancer, dermatitis, superficial mycoses; inflammation, tinea pedis, tinea cruris, and tinea corporis, Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyton floccosum , and Microsporum canis , candidiasis (moniliasis), Candida albicans , tinea (pityriasis) vesicolor, Malassezia furfur , acute myeloid leukemia, acute lymphoid leukemia, chronic myelogenous leukemia, lymphoma or multiple myeloma.
• METHODS OF FORMING CYCLOPIROX OR DERIVATIVES THEREOF IN A SUBJECT BY ADMINISTRATION OF PRODRUG
  申请人：The University of Kansas

  公开号：US20160095870A1

  公开（公告）日：2016-04-07

  A method of forming a compound in a subject can include: providing a composition having a prodrug compound represented by a structure of Formula 1 or stereoisomer thereof or pharmaceutically acceptable salt thereof; and administering the composition to a subject such that the prodrug compound has a phosphoryloxyalkyl prodrug moiety removed therefrom to form the compound in the subject and to form the separate phosphoryloxyalkyl compound. The prodrug can be included in a pharmaceutical composition for use in treatment of fungus, various cancers (e.g., bladder, breast, etc.), dermatitis, superficial mycoses; inflammation, tinea pedis, tinea cruris, and tinea corporis, Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyton floccosum , and Microsporum canis , candidiasis (moniliasis), Candida albicans , tinea (pityriasis) vesicolor, Malassezia furfur , acute myeloid leukemia, acute lymphoid leukemia, chronic myelogenous leukemia, lymphoma or multiple myeloma.